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Experimental autoimmune encephalomyelitis (EAE)
serves as the prototypic model for T cell–mediated autoim-
munity. EAE has striking similarities with the human dis-
ease acute disseminated encephalomyelitis, a complication
seen with vaccination and after certain viral infections.
EAE has been used as a model to help understand the
pathogenesis of multiple sclerosis (MS) and to help identify
potential therapeutic candidates for this disease (Table I),
Until now, research has focused nearly exclusively on the
role of CD4
 
 
 
 T cells in EAE (1–3). In this issue and in a
recent publication in the 
 
Journal of Immunology
 
 (4, 5), a
pathogenic role of CD8 T cells in EAE has now been de-
scribed. Lesions in inflammatory infiltrates in the brain and
spinal cord of MS patients (6, 7), and in brain lesions in
EAE (8), include both CD4 and CD8 T cells. Therefore, it
is important to seriously consider both of these T cell sub-
sets in the evolution of this mysterious disease which afflicts
nearly a million individuals worldwide.
Over 4,500 papers have been published on the EAE
model since it was first described (9, 10). 
 
The Journal of Ex-
perimental Medicine 
 
has published many of the landmark pa-
pers on EAE, dating back 
 
 
 
60 yr to the publication of
River’s classic paper on the induction of encephalomyelitis
in primates with extracts from rabbit brain (11). Kabat’s de-
scription of the use of Freund’s adjuvant in the induction of
EAE appeared in 
 
The Journal of Experimental Medicine 
 
54 yr
ago (12). The use of Complete Freund’s Adjuvant to in-
duce EAE reduced the number of injections required in
River’s model from 85 over 1 yr to a single injection of
brain extract (12)! The use of Freund’s Adjuvant to initiate
EAE probably induced biases in the types of cells that ex-
panded after such immunization. T cells that could be ex-
panded after injection of Complete Freund’s Adjuvant
were mostly Th1, probably due to the CpG motifs in the
DNA from the killed mycobacteria tuberculosis. Thus, via
history and peer selection 
 
The Journal of Experimental Medi-
cine
 
 has traditionally been the forum for new developments
in this model.
Until now almost all of the work done in the EAE
model has focused on CD4 T cells and the resulting cas-
cade of cytokines and chemokines involved in pathogene-
sis. Recently, again in this journal, LaFaille and Tonegawa
showed that CD4
 
 
 
, myelin-specific T cells induced EAE
predominantly, but not always, via production of Th1 cy-
tokines (13). Indeed they showed that Th2 T cells could
trigger EAE (13). Such Th2 myelin-specific T cells can also
cause anaphylaxis, creating a new version of “horror auto-
toxicus” with “allergy to self” (14). Thus, EAE has been a
durable model, and may indeed come in at least two forms:
experimental 
 
autoimmune
 
 encephalomyelitis and experi-
mental 
 
allergic
 
 encephalomyelitis (9, 14). We now must dis-
sect even deeper layers of our understanding of EAE. Not
only are their roles for Th1 and Th2 T cells, and not only
are there autoimmune and allergic forms of EAE, we now
must deal with at least two versions of T cells, those bear-
ing the CD4 molecule and those bearing the CD8 mole-
cule, for both of them can induce this model disease.
Goverman and colleagues have shown that CD8
 
 
 
 T cell
clones, specific for a class I restricted–fragment of myelin
basic protein, produce severe EAE with paralysis and other
neurological deficits (4). The strategy employed by Gover-
man and colleagues is noteworthy. They first demonstrated
the existence of cytotoxic T cells for myelin in C3H.
 
shi
 
mice. These mice have the “shiverer” mutation, rendering
them deficient in one of the major constituents of the my-
elin sheath, myelin basic protein. Defective myelination
causes these mice to have a tremor resembling shivering.
The C3H.
 
shi
 
 mice had cytotoxic T cells specific for the
epitope MBPp79–87 restricted by H-2K. In normal C3H
mice, cytotoxic T cell clones could be established after im-
munization with MBP79–87 in Complete Freund’s Adju-
vant. So, once the class I–restricted epitope was known,
 
there was no intrinsic barrier for expansion of class I–restricted
CD8 T cells that are cytotoxic for myelin, after immuniza-
tion with MBPp79–87 in Complete Freund’s Adjuvant.
These cytotoxic T cells in Goverman’s model have pro-
duced the newest version of EAE.
Cytoxic CD8 T cell clones injured brain and induced
ataxia, spasticity, and hind limb paralysis in mice after intra-
venous injection. Neuropathology revealed perivascular
cuffs in the vascular walls of the brain. Interestingly, CD4-
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induced EAE produces perivascular cuffs in the blood ves-
sel walls in brain and in spinal cord. Demyelination was
noted (4). In the paper by Sun and colleagues (5), CD8
 
 
 
 T
cells reactive to myelin oligodendroglial glycoprotein pep-
tide 35–55 induced massive inflammation and demyelina-
tion in the central nervous system. Thus there is strong ev-
idence from two independent labs, with data emerging
simultaneously, to support a major role for CD8 T cells in
autoimmune demyelination.
The major differences between CD4-induced EAE and
CD8-induced EAE appear in attempts at modulating dis-
ease with agents that block the cytokines TNF-
 
 
 
 and IFN-
 
 
 
.
The roles for these cytokines in MS and EAE remain
controversial. When EAE is induced by CD4
 
 
 
 T cells, dis-
ease is blocked with antibodies to TNF-
 
 
 
 or fusion pro-
teins that block TNF receptor. With one notable excep-
tion, described by Bernard and colleagues, EAE induced by
CD4 T cells is usually ameliorated when TNF-
 
 
 
 or lym-
photoxin is inhibited (references 10 and 15, and Table II).
In contrast, in the model of CD8-induced EAE devised by
Goverman’s group (4), TNFR:FC has no effect, while in
MS TNFR:FC actually worsens disease (16). Further, a
large number of studies in EAE show that EAE is blocked
by administration of rIFN-
 
 
 
 (10). Moreover, in Gover-
man’s study showing EAE induced with CD8 T cells (4),
anti–IFN-
 
  
 
antibody reduces disease, while in EAE in-
duced by CD4
 
 
 
 T cells, anti–IFN-
 
 
 
 actually worsens dis-
ease. In MS a clinical trial of rIFN-
 
 
 
 was discontinued pre-
maturely due to worsening of disease (17). Thus, when
considering the potential pathologic roles of TNF and
IFN-
 
 
 
, there is more concordance between the model of
CD8
 
 
 
-induced EAE and MS than the corresponding
 
CD4
 
 
 
 models of EAE and MS (Table II). Thus, to some
extent the CD8 model of EAE reflects some of the results
obtained in clinical trials of MS better than the CD4-
induced models of EAE.
The role of CD8 T cells in MS and its experimental
models has remained enigmatic. There have been bold at-
tempts to delete CD4 T cells in MS with chimerized mono-
clonal antibodies that are cytotoxic. While it is certain
that CD4
 
 
 
 T cells are critical in EAE induced with class II–
restricted T cell clones or with Complete Freund’s Adju-
vant (18, 19), the role of CD4
 
 
 
 
 
T cells in MS is far less
clear. Extensive depletion of CD4
 
 
 
 T cells in MS made
small but significant improvements in relapse rates and re-
duced the level of inflammatory activity in the brain, de-
tected with magnetic resonance imaging (20, 21). A Phase
II placebo–controlled double-masked study showed that
“the degree of depletion of CD4
 
  
 
cells was important with
regard to treatment efficacy. Using CD4 counts as a covari-
ate, there was a statistically significant effect on the number
of active lesions 
 
 
 
18 mo (
 
P
 
 
 
  
 
0.04). There was a statisti-
cally significant reduction of 41% in the number of clinical
relapses (a secondary efficacy parameter) after 9 mo (
 
P 
 
 
 
0.02), which was still present after 18 mo.” (21) Perhaps
similar depletion studies ought to be contemplated in MS
with anti-CD8 antibodies, or even a combination of anti-
CD4 and anti-CD8 antibodies. The new models proposed
by J. Goverman and by D. Sun certainly provide a basis for
considering this strategy.
The immunochemistry of T cell interactions with anti-
gen and recent genetic studies on susceptibility to disease
 
Table I.
 
Comparisons Between MS and EAE, Clinical, 
Pathological, and Genetic
 
Clinical Presentation MS EAE
Relapses and remissions present present
Paralysis present present
Ataxia present present
Visual impairment present present
Genetics MS EAE
MHC-linked susceptibility yes yes
Females more susceptible yes yes
Pathology in Lesions MS EAE
Clonal CD4
 
 
 
 T cells react to myelin present present
Clonal CD8
 
 
 
 T cells react to myelin present present
Perivascular cuffs present present
Antibodies to myelin present present
 
 
 
4 integrin, complement present present
TNF-
 
 
 
, IFN-
 
 
 
present present
Demyelination present present
Axonal dystrophy present present
 
Table II.
 
Comparisons of Therapeutic Approaches in MS,
CD4-induced and CD8-induced EAE
 
Therapy in CD4-induced EAE MS EAE
IFN-
 
 
 
, systemic worsens cures
Anti–IFN-
 
 
 
not done worsens
Anti-TNF worsens cures
 
a
 
TNF, systemic not done cures
 
b
 
TNF receptor blockade worsens improves
Anti-
 
 
 
4 integrin beneficial cures
Copaxone beneficial improves
Anti-CD4 beneficial cures
Therapy in
CD8-induced EAE MS EAE
IFN-
 
 
 
, systemic worsens not done
Anti–IFN-
 
 
 
not done cures
TNF receptor blockade worsens no effect
Anti-
 
 
 
4 integrin beneficial not yet done
Copaxone beneficial not yet done
Anti-CD8 not yet done cures
 
a
 
Reference 10.
 
b
 
Reference 15. 
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have revealed new evidence supporting the importance of
both CD4 and CD8 T cells in autoimmune disease. T cells
recognize antigen via a complex interaction with antigen
embedded in a binding cleft on MHC class I or class II
molecules. CD4 anchors the T cell to MHC class II, while
CD8 anchors the T cell to MHC class I. Both MHC class I
and class II genes are associated with susceptibility to MS
(22–24). Moreover, the MHC class I and II HLA genes are
in strong linkage disequilibrium, suggesting that they com-
monly segregate together on the chromosome, giving
broad genotypes involving a constellation of alleles from
Class I HLA-A and -B genes, along with MHC class II
HLA-DR and -DQ genes. There are common extended
genotypes for susceptibility to MS involving HLA-A, -B,
-DR, and -DQ. Thus there are cogent reasons to look not
only for the pathogenic roles of CD4 T cells, which bind
HLA class II–loaded with antigen, but also for a pathogenic
role for CD8 T cells binding HLA class I plus antigen. Fi-
nally, HLA class I and II gene products are elevated on in-
flamed oligodendroglial cells and these may further serve as
targets for both CD4 and CD8 T cells. Thus, the immuno-
genetics of MS provide a basis for understanding why both
CD4 and CD8 T cells may play critical roles in the patho-
genesis of demyelinating disease.
The CD8 T cell deserves at least as much attention as the
CD4 T cell, as a prime suspect as one of the T cells causing
demyelination, and therefore potentially a major culprit in
MS. There are clonal expansions of both CD4 and CD8 T
cells in the brains of MS patients. Some of these clones of T
cells have specificity for myelin proteins. Therefore, it is a
valid expectation that some of the clonally expanded CD4
 
 
 
and CD8
 
 
 
 T cells in MS brain may turn out to be rogues
and villains (25, 26). Their containment may be beneficial
for those suffering from MS.
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